美国食品和药物管理局（FDA）已批准武田制药抗高血压药Edarbi在美国上市。

该药的商品名为“Edarbi”，是血管紧张素Ⅱ受体阻滞剂（ARB）阿齐沙坦酯（azilsartan medoxomil）的一个衍生物。

Edarbi可阻滞血管紧张素II引起的血管收缩，从而使血压下降。

武田制药北美公司首席执行官Shinji Honda表示对该药获批感到非常高兴，他说，“通过该新药的发现、开发和商业化，武田致力于将Edarbi等新药推向市场。Edarbi对高血压患者以及为其提供治疗的医护人员是一个重要的新治疗选择。”

将可得到80 mg和40 mg剂量的Edarbi，推荐剂量设定在80 mg每天1次。对于用高剂量利尿药治疗减低机体内盐的患者可用40 mg剂量。

批准日期：2011年2月25日；公司：武田制药[Takeda Pharmaceutical Company Limited]

EDARBI

Generic Name for EDARBI Azilsartan medoxomil 40mg, 80mg; tabs. Legal Classification: Rx Pharmacological Class for EDARBI Angiotensin II receptor blocker. Manufacturer of EDARBI Takeda Pharmaceuticals America, Inc. Indications for EDARBI Hypertension. May be used alone or in combination with other antihypertensive agents. Adult dose for EDARBI ≥18yrs: Monotherapy, not volume-depleted: 80mg once daily. Volume-depleted (eg, concomitant high-dose diuretics): initially 40mg once daily. Children's dosing for EDARBI <18yrs: not recommended. Warnings/Precautions for EDARBI Correct salt/volume depletion before starting therapy, or reduce initial dose; monitor for hypotension. Severe CHF. Renal artery stenosis. Renal impairment (monitor serum creatinine). Pregnancy (Cat. C in 1st trimester; Cat. D in 2nd and 3rd trimesters; avoid). Nursing mothers: not recommended. Interactions for EDARBI May be antagonized by, and renal toxicity potentiated by NSAIDs, including selective COX-2 inhibitors (monitor renal function periodically in elderly and/or volume-depleted). Adverse Reactions for EDARBI Diarrhea; rare: orthostatic hypotension, dizziness, nausea, asthenia, fatigue, muscle spasm, cough. How is EDARBI supplied? Tabs—30, 90